Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

Tait Shanafelt, Clive Zent, John Byrd, Charles Erlichman, Betsy Laplant, Asish Ghosh, Timothy Call, Miguel Villalona-Calero, Diane Jelinek, Deborah Bowen, Kristina Laumann, Wenting Wu, Curtis Hanson, Neil Kay

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL. Collectively, 46 patients were accrued to trials of single-agent anti-VEGF antibody (bevacizumab, n = 13) or one of two receptor tyrosine kinase inhibitors (AZD2171, n = 15; sunitinib malate, n = 18). All patients have completed treatment. Patients received a median of two cycles of bevacizumab, AZD2171, or sunitinib malate. All three trials were closed early due to lack of efficacy. No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.

Original languageEnglish (US)
Pages (from-to)2222-2229
Number of pages8
JournalLeukemia and Lymphoma
Volume51
Issue number12
DOIs
StatePublished - Dec 2010

Keywords

  • Chronic lymphocytic leukemia
  • angiogenesis
  • bevacizumab
  • receptor tyrosine kinase inhibitor
  • therapy
  • vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this